Premium
Predictors of early treatment discontinuation in a cohort of patients treated with boceprevir‐based therapy for hepatitis C infection
Author(s) -
Majid A.,
McAninch J.,
Morgan D. J.,
El Kamary S. S.,
Zhan M.,
Kapelusznik L.,
Talwani R.
Publication year - 2014
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12201
Subject(s) - boceprevir , medicine , discontinuation , tolerability , cohort , rescue therapy , hepatitis c , telaprevir , chronic hepatitis , immunology , adverse effect , ribavirin , virus
Summary In this real‐world cohort, 49% of patients stopped boceprevir‐based hepatitis C therapy early, with only 20% stopping due to treatment futility. Having more comorbidities was significantly associated with early discontinuation. Tolerability of boceprevir‐based regimens may be substantially worse than reported in clinical trials, particularly for patients with comorbidities.